Keith P. Wilson, Ph.D.

President and Chief Scientific Officer, Takeda San Diego, Inc.

Dr. Wilson is President and Chief Scientific Officer of Takeda San Diego, Inc., a US-based IND engine for Takeda Pharmaceuticals of Japan. The San Diego site also supports Takeda's global structural biology needs, and is actively expanding Takeda's US science, business, and intellectual property presence.

Dr. Wilson joined Syrrx, a privately held structure-based drug discovery company, in 2002 as Vice President of Structural Biology. He was promoted to Vice President of Business Development in 2003 while retaining his structural biology leadership role. He continued to direct both groups prior to being promoted to President and CSO of Takeda San Diego.

From 2002 - 2007, Dr. Wilson was instrumental in reshaping the company from a platform to a drug discovery focused company, and in building its pipeline. He also played an essential role in establishing, negotiating, and/or managing strategic Syrrx partnerships with Roche, Pharmacia, and Biogen-IDEC, and in the acquisition and integration of Paradigm Therapeutics in the U.K. by Takeda (now Takeda Cambridge).

Prior to joining Syrrx, Dr. Wilson gained 10 years of structure-based drug discovery experience at Vertex Pharmaceuticals, where his scientific efforts supported multiple IND filings across 7 consecutive projects. He also served as the co-project leader for the 165 person Vertex-Novartis kinase alliance.

Dr. Wilson received his formal education at the University of Oregon (Ph.D., physics, 1989) and Colby College (B.A., physics, 1984), where he graduated magna cum laude and was awarded the William A. Rogers prize in physics. Dr. Wilson is an author on over 30 peer-reviewed publications, and co-inventor of multiple compounds including telaprevir for the potential treatment of Hepatitis C.